J B Chemicals & Pharmaceuticals Ltd Q4 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/z3771n8nnyy90vth042gag8g.pdf

Key Takeaways


Domestic Business & Brand Performance

Chopra: "The objective of sharing this data of the last 3 years... is more to share with colleagues on the call is how J. B. as a company, J. B. Pharma as a company has progressed over the last 3 years consistently, not only in terms of top line, but, overall, in EBITDA, in profits and also in net working capital and operating cash flow."

Ophthalmology Portfolio Integration

Chopra: "We would also like to expand our portfolio in the coming time in the world of dry eyes, where the portfolio is not there and antioxidants for ophthalmology. We may get into mid to long-term in-licensing partnering for some biologics in the world of ophthalmology."

CDMO Business & Growth Levers

Chopra: "You too also understand that this business has got high gestation period. It takes time for any new lozenges to being commercialized because the way it works with the reference sample."

International Business Restructuring


Margins & Profitability


Guidance & Commitments

CommitmentSpecificsTimeline
Operating EBITDA margin26% to 28% (raised from 25%–27%)FY25
Overall revenue growth (ex-ophthal)12% to 14%FY25
Domestic business outperformanceOutperform IPM by 200 bpsOngoing
CDMO growth12% to 14%, accelerating to high teensFY25, with high teens from Q3 onward
Ophthal monthly revenue run rate₹15–16 croresTarget for FY25
Gross marginCloser to 65%Coming 2 years
EBITDA growth16% to 18%FY25
Domestic + CDMO revenue share75% to 80% of overall businessMidterm
CDMO revenue aspiration$100 million3–5 years

Key Metrics

MetricQ4 FY24
Revenue₹862 cr, +13% YoY
FY24 revenue₹3,484 cr, +11% YoY
Revenue growth excluding South Africa+17% in Q4, +14% in FY24
Gross profit margin65.2%, expanded 130 bps YoY
FY24 gross profit margin66.1%, expanded 320 bps YoY
Operating EBITDA (excl. ESOP cost)₹210 cr, +16% YoY
FY24 operating EBITDA (excl. ESOP cost)₹939 cr, +23% YoY
Operating EBITDA margin guidance26% to 28%, revised upward from 25%–27%
Domestic business revenue₹465 cr, +22% YoY
Domestic business FY24 revenue₹1,897 cr, +16% YoY
International business revenue₹397 cr, +4% YoY reported; +15% excluding South Africa
CDMO revenue₹109 cr, +9% YoY
CDMO FY24 revenue₹432 cr
CDMO as a share of international business27%, up from 21% in FY21
MR productivity₹7 lakhs per month per medical rep, expected to grow 8%–10%
IPM growth vs J.B. growth10% for J.B. vs 7.6% industry, IQVIA MAT March 2024
Sporolac franchise revenue₹122 cr, 33% CAGR over 3 years, IQVIA MAT March 2024
Azmarda revenue₹75 cr
Razel growth+24% YoY
Ophthalmology acquisition month-on-month growth+11% in March 2024, IQVIA
Cilacar volume growth+10% in FY24, IQVIA
Cilacar T volume growth+10% in FY24, IQVIA
Nicardia volume growth+5% in FY24, IQVIA
Razel volume growth+22% in FY24, IQVIA
Chronic portfolio revenueSurpassed ₹1,000 cr, MAT March 2024
South Africa private business contribution70%, up from 40% three years ago
Operating cash flow FY24₹801 cr, more than doubled from ₹315 cr in FY21
Operating cash flow as a percentage of operating EBITDA85%, up from 56% in FY21
Net working capital87 days, reduced from 98 days three years ago
ROCE27% in FY24, up from 21% in FY23
Gross debt₹357 cr as of 31 March 2024, down from ₹548 cr a year ago
Net cash positionNet cash positive as of March 2024
CDMO lozenges capacity200 cr lozenges annualized; current run rate 100 cr lozenges
Ophthalmology MR count104, ramped from ~75 at acquisition
New product contribution to overall growth3%
Ophthal business monthly revenue run rate target₹15 cr to ₹16 cr
ESOP cost expected for FY25~₹40 cr
Azmarda market share14% to 15%
Ophthal portfolio gross margin dilution~150 bps dilutive
Ophthal portfolio EBITDA margin dilution~50 bps dip expected in FY25 and FY26
Overall company top line growth guidance (excl. ophthal)12% to 14%
India, CDMO, and ROW growth guidance12% to 14%
US, Russia, South Africa growth guidanceHigh single digit, around 8% to 9%
CDMO revenue aspiration$100 mn, journey for next 3 to 5 years
Ophthalmology market size in IndiaClose to ₹4,000 cr, growing at 14%
Acquired ophthal portfolio covered marketClose to ₹2,800 cr
Gross margin outlook for coming 2 yearsCloser to 65%